Comparison of [ 111 In]octreotide Scintigraphy and [ 68 Ga]DOTATOC PET in Gastroenteropancreatic Neuroendocrine Tumors: Concordance of Krenning Scores and Implications for Peptide Receptor Radionuclide Therapy Eligibility
Neuroendocrinology · 12.06.2026 · 1-8
DOI: 10.1159/000552968 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Neuroendocrinology, online erschienen am 12.06.2026. Verfasst von Roberto Fedrigo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Octreotide, Pancreatic Neoplasms, Positron-Emission Tomography. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
Background
Peptide receptor radionuclide therapy (PRRT) is an established treatment for somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), with eligibility determined by the Krenning score. While SSTR PET provides greater sensitivity than octreotide scintigraphy, its impact on PRRT eligibility remains unclear. We compared Krenning scores between [111In]octreotide scintigraphy and [68Ga]DOTATOC PET and assessed eligibility under NETTER-1 and NETTER-2 criteria.
Methods
We retrospectively assessed tumor Krenning scores in 115 patients with well-differentiated GEP-NETs who underwent both [111In]octreotide scintigraphy and [68Ga]DOTATOC PET. PRRT eligibility was defined according to NETTER-1 (Krenning ≥2) and NETTER-2 (Krenning ≥3) criteria. Logistic regression identified predictors of Krenning ≥3 on SSTR PET. Quantitative PET analysis was performed for patients with positive baseline [68Ga]DOTATOC PET scans.
Results
Median Krenning scores were higher with SSTR PET than planar imaging (3 [IQR 3–4] vs. 2 [IQR 0–3], p < 10−8). NETTER-1 eligibility increased from 59.1% with planar imaging to 81.7% with PET (p < 10−3), and NETTER-2 from 48.7% to 76.5% (p < 10−4). Among patients eligible on planar imaging, 95.6% (NETTER-1) and 98.2% (NETTER-2) had concordant PET findings. Conversely, 61.7% (NETTER-1) and 55.9% (NETTER-2) of patients ineligible on planar imaging were reclassified as eligible with PET. Metastatic disease was associated with higher SSTR PET uptake (odds ratio 9.5 [95% confidence interval: 2.7–32.8], p < 10−3). SUVmax discriminated patients with Krenning ≥3 using an optimal threshold of 9.2 (AUC 0.93). Conclusions: [68Ga]DOTATOC PET yields higher Krenning scores and increases PRRT eligibility compared with [111In]octreotide scintigraphy. PET may be unnecessary for clearly positive planar studies but identifies additional candidates with borderline or negative planar results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada.
- Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
- Department of Molecular Imaging and Therapy, BC Cancer, Vancouver, British Columbia, Canada.
- Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada.
- Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada, jonathan.loree@bccancer.bc.ca.
- Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada, jonathan.loree@bccancer.bc.ca.
Zitieren
APA
Fedrigo, R., Harsini, S., Murtha, L., Solar Vasconcelos, J. P., Uribe, C., Wilson, D., Benard, F., Alberts, I., Martineau, P., & Loree, J. M. (2026). Comparison of [ 111 In]octreotide Scintigraphy and [ 68 Ga]DOTATOC PET in Gastroenteropancreatic Neuroendocrine Tumors: Concordance of Krenning Scores and Implications for Peptide Receptor Radionuclide Therapy Eligibility. Neuroendocrinology, 1-8. https://doi.org/10.1159/000552968
Vancouver
Fedrigo R, Harsini S, Murtha L, Solar Vasconcelos JP, Uribe C, Wilson D, et al. Comparison of [ 111 In]octreotide Scintigraphy and [ 68 Ga]DOTATOC PET in Gastroenteropancreatic Neuroendocrine Tumors: Concordance of Krenning Scores and Implications for Peptide Receptor Radionuclide Therapy Eligibility. Neuroendocrinology. 2026:1-8. doi:10.1159/000552968
BibTeX
@article{Fedrigo2026,
author = {Fedrigo, Roberto and Harsini, Sara and Murtha, Luke and Solar Vasconcelos, Joao Paulo and Uribe, Carlos and Wilson, Don and Benard, Francois and Alberts, Ian and Martineau, Patrick and Loree, Jonathan M},
title = {Comparison of [ 111 In]octreotide Scintigraphy and [ 68 Ga]DOTATOC PET in Gastroenteropancreatic Neuroendocrine Tumors: Concordance of Krenning Scores and Implications for Peptide Receptor Radionuclide Therapy Eligibility},
journal = {Neuroendocrinology},
year = {2026},
pages = {1--8},
doi = {10.1159/000552968}
}
EUVIMED